Surgeon‐led prostate cancer lymph node staging: pathological outcomes stratified by robot‐assisted dissection templates and patient selection

Abstract

The net benefit of E-PLND remains uncertain, and therapeutic impact will probably require a randomised trial, given the strong selection criteria. E-PLND contributes to oncological staging in a significant number of high- and intermediate-risk patients, and should be bilateral. Immediate concerns include longer operative times, but no higher complication rates.